HER2DX for Early Stage HER2+ Breast Cancer Treatment Decisions
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- European Institute of Oncology · Other
This trial is looking for adults with early stage HER2+ breast cancer. Participants will help evaluate how a specific test, HER2DX, influences treatment decisions made by their healthcare team.
You may be able to join if
- I am at least 18 years old
- I have been diagnosed with HER2+ breast cancer
- My breast cancer is Stage I, II, or III
- I do not have distant metastases
- I am a candidate for neoadjuvant or adjuvant therapy
- I can give my written informed consent for the study
You may not be able to join if
- I have HER2- breast cancer
- I have Stage IV breast cancer
- I cannot provide informed consent
- I am unwilling to participate
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityTo prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.
Loading trial locations…